AstraZeneca (NYSE: AZN) secured US Food and Drug Administration (FDA) accelerated approval for ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor. The treatment targets adult patients with hormone receptor-positive, HER2-negative advanced breast cancer upon detection of ESR1 mutations.

The approval marks the company’s tenth FDA grant this year and its fourth in breast cancer. It is based on the pivotal SERENA-6 Phase III trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. A companion diagnostic test to detect emerging ESR1 resistance mutations in circulating tumor DNA was also approved concurrently.

Trial Efficacy and Safety

In the planned interim analysis of the SERENA-6 trial, the combination reduced the risk of disease progression or death by 56% versus standard-of-care treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The hazard ratio was 0.44 (95% CI: 0.31-0.60; p<0.00001), with median progression-free survival (PFS) of 16.0 months compared to 9.2 months.

Subsequent pre-planned analysis demonstrated a statistically significant benefit in time to second disease progression (PFS2), showing 25.7 months versus 19.1 months (HR: 0.63; p=0.00373). Overall survival data remained immature but continued to mature in favor of the combination (HR: 0.87).

The safety profile was consistent with known profiles of each medicine, with no new concerns identified. Discontinuations were very low and similar across arms. Common adverse reactions included decreased neutrophils (68%) and leukocytes (66%).

Clinical Context

Approximately 30% of patients with endocrine-sensitive HR-positive disease develop ESR1 mutations during first-line treatment before disease progression. These mutations are a key driver of endocrine resistance and are associated with poor outcomes. The trial design used ctDNA monitoring via blood tests every two to three months to identify patients for early therapy switches.

What the Numbers Show

The 56% reduction in progression or death risk translates to a 6.8-month extension in median progression-free survival (16.0 months vs 9.2 months). This magnitude of improvement suggests that detecting ESR1 mutations via ctDNA before radiographic progression allows for earlier intervention, potentially delaying the onset of more aggressive disease states where treatment options are limited.

ETCAMAH is approved in more than 30 countries, including the EU, Japan, Canada, and the UK. Continued US approval may be contingent upon verification of clinical benefit in confirmatory trials.

AstraZeneca Plc (NYSE: AZN) reported dual advances in its oncology portfolio on Tuesday, securing a European Union regulatory approval for its breast cancer treatment and posting positive Phase 3 trial results for a lung cancer combination therapy.

The pharmaceutical major announced that the European Commission approved Enhertu, developed jointly with Daiichi Sankyo, as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. This authorization follows a positive recommendation from the European Medicines Agency’s medicinal committee.

Enhertu Approval Details

The regulatory decision was based on data from the DESTINY-Breast09 trial. The study showed that the Enhertu combination therapy with pertuzumab reduced the risk of disease progression or death by 44% compared to standard THP therapy.

European regulators are also reviewing Enhertu for residual invasive HER2-positive breast cancer, based on data from the DESTINY-Breast05 study.

Lung Cancer Trial Results

In parallel, AstraZeneca released high-level outcomes from the SANOVO Phase 3 study. The trial evaluated Tagrisso combined with Orpathys in untreated patients with epidermal growth factor receptor-mutated, locally advanced or metastatic non-small cell lung cancer featuring MET overexpression.

The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful progression-free survival benefit over Tagrisso monotherapy. This benefit was observed across both high MET and intention-to-treat patient groups. The combination also showed encouraging clinical trends in overall survival, a secondary endpoint.

AstraZeneca jointly develops Orpathys with HUTCHMED Ltd. (NASDAQ: HCM) but holds sole commercialization rights. Previous studies, including SACHI and SAFFRON, had already established the combination’s clinical benefits, leading to an existing approval in China.

What the Numbers Show

The clinical data highlights a distinct divergence in survival outcomes between the new regimen and standard care. The 13.8-month extension in median progression-free survival (from 26.9 months to 40.7 months) underscores the magnitude of the risk reduction cited in the DESTINY-Breast09 trial.

Market Reaction

AstraZeneca shares were down 0.81% at $160.81 during premarket trading on Tuesday, according to Benzinga Pro data.